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Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes
Abstract
Spinal muscular atrophy (SMA) is one of the major genetic disorders associated with infant mortality. More
than 90% cases of SMA result from deletions or mutations of Survival Motor Neuron 1 (SMN1) gene. SMN2, a
nearly identical copy of SMN1, does not compensate for the loss of SMN1due to predominant skipping of
exon 7. However, correction of SMN2 exon 7 splicing has proven to confer therapeutic benefits in SMA
patients. The only approved drug for SMA is an antisense oligonucleotide (Spinraza™/Nusinersen), which
corrects SMN2 exon 7 splicing by blocking intronic splicing silencer N1 (ISS-N1) located immediately
downstream of exon 7. ISS-N1 is a complex regulatory element encompassing overlapping negative motifs
and sequestering a cryptic splice site. More than 40 protein factors have been implicated in the regulation of
SMN exon 7 splicing. There is evidence to support that multiple exons of SMN are alternatively spliced during
oxidative stress, which is associated with a growing number of pathological conditions. Here, we provide the
most up to date account of the mechanism of splicing regulation of the SMN genes.
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Abstract
Spinal muscular atrophy (SMA) is one of the major genetic disorders associated with infant 
mortality. More than 90% cases of SMA result from deletions or mutations of Survival Motor 
Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, does not compensate for the 
loss of SMN1 due to predominant skipping of exon 7. However, correction of SMN2 exon 7 
splicing has proven to confer therapeutic benefits in SMA patients. The only approved drug for 
SMA is an antisense oligonucleotide (Spinraza™/Nusinersen), which corrects SMN2 exon 7 
splicing by blocking intronic splicing silencer N1 (ISS-N1) located immediately downstream of 
exon 7. ISS-N1 is a complex regulatory element encompassing overlapping negative motifs and 
sequestering a cryptic splice site. More than 40 protein factors have been implicated in the 
regulation of SMN exon 7 splicing. There is evidence to support that multiple exons of SMN are 
alternatively spliced during oxidative stress, which is associated with a growing number of 
pathological conditions. Here, we provide the most up to date account of the mechanism of 
splicing regulation of the SMN genes.
Keywords
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1. Introduction
Pre-mRNA splicing is an essential process in eukaryotic cells during which noncoding 
(intronic) sequences are removed and coding (exonic) sequences are joined together to 
generate mRNA. The complex reaction of splicing is catalyzed by a spliceosome, a 
macromolecular machinery [1]. The most critical step of a splicing reaction is the accurate 
determination of the 5′ and 3′ splice sites (5′ss and 3′ss) that mark the beginning and end 
of an intron, respectively [2]. All intron-containing human genes have potential to be 
alternatively spliced, generating multiple mRNA isoforms from a single gene [3]. Decision 
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to include or exclude an exon during pre-mRNA splicing is dictated by a combinatorial 
control of cis -elements and transacting factors. The same cis -element when presented in a 
different context may have different effects on splicing [4, 5]. Hence, the relative impact of a 
cis -element cannot be accurately predicted, it [the impact] requires experimental validation. 
Interpreting the consequences of a splicing-associated mutation remains a puzzle, since a 
single mutation can cause at least one of the following changes: loss of a positive element, 
gain of a negative element, change of a structural context, and nonsense-mediated decay 
(NMD) due to creation of an in-frame premature termination codon (PTC) [6, 7]. Rules of 
splicing are quite flexible and are heavily influenced by the relative abundance of various 
splicing factors in different tissues [8]. Further, splicing is coupled to other events including 
transcription, the 5′ capping, and the 3′ polyadenylation [6, 9]. Therefore, deciphering the 
mechanism by which a given exon is alternatively spliced remains a daunting task. A 
growing number of disorders are linked to aberrant splicing [10, 11]. Each case of aberrant 
splicing calls for an in-depth analysis of the context-specific rules so that strategies to 
manipulate splicing could be devised in a gene-specific manner.
Humans carry two near identical copies of the Survival Motor Neuron gene: SMN1 and 
SMN2 [12]. Both SMN genes code for SMN, a multifunction protein essential for the 
survival of all animal cells. The ability of SMN to interact with nucleic acids and proteins 
allows it to participate in various cellular processes, including but not limited to 
transcription, splicing, translation, macromolecular trafficking, and signal transduction [13]. 
The critical difference between SMN1 and SMN2 is the splicing of exon 7. Unlike SMN1 
exon 7, SMN2 exon 7 is predominantly skipped in most tissues, except in testis [14]. The 
exon 7-skipped transcript generated by SMN2 codes for SMNΔ 7, a partially functional and 
unstable protein [15–17]. Loss of SMN1 creates SMN deficit, leading to spinal muscular 
atrophy (SMA), a major genetic disease of children and infants [18, 19]. Aberrant expression 
and/or localization of SMN have been associated with several other diseases, including 
amyotrophic lateral sclerosis (ALS), metabolic disorders, male infertility, and stress-
associated disorders [14, 20–22]. Correction of SMN2 exon 7 splicing has proven to confer 
therapeutic benefits in mouse models of SMA [23, 24]. The first approved drug for SMA, 
Nusinersen (Spinraza™), is an antisense oligonucleotide (ASO) that promotes inclusion of 
SMN2 exon 7 by sequestering an inhibitory cis -element called Intronic Splicing Silencer 
N1 or ISS-N1 [25, 26]. In this review, we describe studies that culminated in the discovery 
of ISS-N1 and analyze how the characterization of ISS-N1 paved the way for a better 
understanding of pre-mRNA splicing in the context of a human disease. We summarize the 
role of various cis-elements and transacting factors that regulate SMN exon 7 splicing. We 
also discuss how lessons learnt from the SMN genes will help find effective therapies for 
genetic diseases associated with aberrant splicing.
2. Organization of Human SMN Genes
The presence of two SMN genes in humans is attributed to the intrachromosomal 
duplication of ~500 kb segment at the 5q13.3 locus on chromosome 5 (Fig. 1A; [12, 35, 
36]). Despite conservation of the coding region of SMN between human and rodents, there 
are substantial differences in the promoter, intronic, and the untranslated regions (UTRs). 
The abundance of Alu elements in human SMN genes suggests a distinct regulation of 
Singh and Singh Page 2
Adv Neurobiol. Author manuscript; available in PMC 2018 June 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
transcription and splicing of SMN in primates. Both SMN genes are ~34 kb long including 
~6 kb long promoter sequence. Several mutations within the promoter region distinguish 
SMN1 from SMN2, suggesting that transcription of these genes might be differentially 
regulated under certain conditions, such as stress (Fig. 1B). Each SMN gene is comprised of 
10 exons, that is, 1, 2A, 2B, 3, 4, 5, 6, 6B, 7 and 8 (Fig. 1C). About 2/3rd of exon 1 serves as 
the 5′UTR, whereas the remaining 1/3rd serves as the coding sequence. Exon 8 is the 
longest exon that encodes the 3′UTR. SMN2 intronic sequences flanking exon 7 contain 
several substitutions and a 5-nt deletion (Fig. 1C). A C-to-T substitution at the sixth position 
(C6U) of exon 7, a G-to-A substitution at the -44th position (G-44A) of intron 6, and an A-
to-G substitution at the 100th position (A100G) of intron 7 are associated with skipping of 
SMN2 exon 7 [37–40]. Recently discovered exon 6B is generated by exonization of an Alu 
element within intron 6 [33]. Another alternative transcript is generated by intron 3 
retention. It codes for a short protein called axonal SMN or aSMN [34]. Considering intron 
3 is conserved between human and mouse, expression of aSMN has been detected in mice as 
well. SMN contains several functional domains and interacts with various proteins. All 
isoforms of SMN possess identical N-terminus that is involved in interactions with both 
proteins and nucleic acids (Fig. 1D; [13]). Recent reports reveal that two antisense 
transcripts, which function as long noncoding RNAs (lncRNAs), are generated from SMN 
locus. One of these lncRNAs termed SMN-AS1 is ~1.6 kb long; it starts and finishes within 
intron 1 (Fig. 1A; [27]). Other one termed SMN-AS1* is ~10 kb long; it starts within 
intergenic region downstream of exon 8 and extends till intron 5 (Fig. 1A; [28]). These 
lncRNAs are specific to humans and their expressions appear to downregulate SMN levels 
through transcriptional control. The significance of fine-tuning of SMN levels within cells is 
underscored by a recent study that showed the pathogenesis of osteoarthritis caused by 
aberrantly high expression of SMN [41]. Factors that regulate SMN transcription and 
splicing modulate SMN levels in a cell-specific manner. Testis happens to be one of the 
tissues with a very high SMN demand. This demand is met by an entirely different set of 
rules that govern transcription and splicing of the SMN genes in testis. Here, we describe a 
critical role of the context-specific cis-elements in SMN splicing and outline the emerging 
rules that are likely to be applicable in most cell types.
3. Regulation of SMN Exon 7 Splicing
Our understanding of SMN exon 7 skipping is continuing to evolve as more and more 
regulatory elements are being discovered within this relatively short exon and its flanking 
intronic sequences. Early studies established that the C6U substitution is the primary cause 
of SMN2 exon 7 skipping [38, 39]. It was also shown that the 3′ss of SMN2 exon 7 is 
weakened by the C6U substitution; but the usage of this 3′ss was enhanced when the 
downstream 3′ss of exon 8 was blocked [42]. Based on bioinformatics predictions and in 
vitro studies, it was proposed that C6U abrogates an enhancer associated with SRSF1 (ASF/
SF2), a member of the highly conserved family of serine/arginine (SR)-rich proteins (Fig. 
2A; [46]). However, this simple “SRSF1 abrogation” hypothesis did not hold true in a 
subsequent cell-based study, where the depletion of SRSF1 did not cause the expected 
enhancement of SMN1 exon 7 skipping (Fig. 2A; [47]). A more recent study suggests a 
surprising dual role of SRSF1 in regulation of SMN2 exon 7 splicing, as both 
Singh and Singh Page 3
Adv Neurobiol. Author manuscript; available in PMC 2018 June 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
overexpression and depletion of SRSF1 caused enhanced skipping of SMN2 exon 7 [48]. An 
alternative hypothesis that C6U creates a silencer associated with hnRNP A1/A2 was 
proposed to explain the skipping of SMN2 exon 7 [47]. Supporting this hypothesis, 
depletion of hnRNP A1/A2 promoted SMN2 exon 7 inclusion [47, 49, 50]. Subsequent 
studies implicated the role of multiple hnRNP A1/A2 sites in the regulation of SMN exon 7 
splicing [37, 51–53]. These findings brought additional complexity to the interpretations of 
the hnRNP A1/A2 depletion experiments, since the observed effect could be attributed to 
abrogation of hnRNP A1/A2 binding to any/all of these sites within SMN2 pre-mRNA. 
Interestingly, hnRNP A1 knockout mice show muscle-specific developmental defects [54]. 
Hence, depletion of hnRNP A1 cannot be exploited for a potential therapy of SMA.
The hnRNP A1/A2 model has been subsequently modified to include Sam68 as an 
additional factor associated with the inhibitory effect of C6U (Fig. 2A; [55]). Consistent 
with the role of hnRNP A1 and Sam68 in SMN2 exon 7 splicing, low extracellular pH that 
increased the nuclear concentrations of hnRNP A1 and Sam68 was found to enhance SMN2 
exon 7 skipping [56]. Another mechanism by which C6U might affect SMN2 exon 7 
splicing is through creation of an extended inhibitory context (Exinct) that consists of 
overlapping negative motifs [57]. Interestingly, C6U also strengthens a predicted terminal 
stem-loop structure, TSL1 (Fig. 2B). Supporting the distinct inhibitory role of TSL1, 
mutations that disrupted TSL1 without abrogating C6U-associated hnRNP A1/A2 motif 
promoted SMN2 exon 7 inclusion [57]. It should be noted that the proposed hypotheses 
associated with the inhibitory effect of C6U are not mutually exclusive. Recent years have 
witnessed a shift in the debate as critical roles of several other negative elements located 
away from the C6U site have been discovered. As per the exon definition model, positive 
factors bridge cross-exon interactions before splicing takes place [58]. An early study 
implicated SFRS10 (Tra2-beta1) as one of the factors that interacts directly with a GA-rich 
sequence located in the middle of exon 7 (Fig. 2A; [59]). Several other proteins, including 
TDP43, SRSF9 (SRp30c), PSF and hnRNP M, were subsequently shown to stimulate exon 7 
inclusion through a direct or indirect interaction with exon 7 (Fig. 2A; [60–64]). 
Surprisingly, a follow-up study in a mouse model of SMA established that SFRS10 is 
dispensable for SMN exon 7 splicing [65]. This finding underscored the complexity of 
splicing regulation when the loss of a positive factor could be tolerated due to the presence 
of other factors with redundant/overlapping functions. Thus far, studies suggest that skipping 
of SMN2 exon 7 is driven largely by the occurrence of negative interactions. The list of 
factors that regulate SMN2 exon 7 is large and continues to grow (Table 1). However, 
interaction sites for most of the identified transacting factors remain unknown. There have 
been very limited attempts to correlate the effect of the naturally occurring mutation within a 
given factor and splicing of SMN exon 7.
3.1. In Vivo Selection of Exon 7
In vivo selection is a powerful method to determine the position-specific role of every exonic 
residue on splicing of a given exon. The feasibility of in vivo selection for an entire exon 
was first demonstrated in the context of SMN1 exon 7 [78]. The method employed a 
partially randomized exon 7 and repeated rounds of selection for sequences that promoted 
exon 7 inclusion [78]. The approach was modeled on in vitro selection of a large sequence 
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used for the simultaneous identification of cis-elements and structural motifs critical for 
RNA-protein interaction [45, 79]. The results of in vivo selection confirmed the presence of 
“Exinct” in the beginning of exon 7 (Fig. 2A; [78]). The findings of in vivo selection also 
uncovered the role of a “conserved tract,” a long stretch of nucleotides in the middle of exon 
7 that constituted a number of overlapping positive cis-elements (Fig. 2A; [78]). In addition, 
the results of in vivo selection revealed the existence of a negative cis-element, the “3′-
cluster,” located toward the end of exon 7 (Fig. 2A; [78]). Of note, the “3′-cluster” overlaps 
with the exonic region that is not conserved between human and rodents, suggesting that 
human SMN exon 7 acquired this negative regulator of splicing after the divergence from the 
common rodent ancestor ~80 million years ago. Major findings of in vivo selection were 
independently confirmed by an antisense microwalk as well as by a machine-learning-based 
simulation study [80, 81]. The most surprising finding of in vivo selection was the 
overwhelming selection of a non-wild type G residue (A54G) at the last position of exon 7 
[78]. Validating experiments confirmed the strong stimulatory effect of A54G substitution 
on SMN2 exon 7 splicing. For instance, substitutions abrogating various positive cis-
elements of exon 7 were fully tolerated in the presence of 54G. Numerous mechanisms by 
which 54G imparts such a strong stimulatory effect on SMN2 exon 7 splicing could be 
envisioned. For example, 54G is predicted to disrupt an inhibitory structure (terminal stem 
loop 2 or TSL2) that sequesters the 5′ss of exon 7 (Fig. 2C). In addition, 54G increases the 
base pairing between U1 snRNP and the 5′ss of exon 7. Indeed, both of these predictions 
turned out to be true [82]. Hence, findings of in vivo selection had a transformative effect on 
our understanding of SMN exon 7 splicing. In particular, they revealed that the 5′ ss of exon 
7 is weak in both SMN1 and SMN2. Subsequent studies focused on the mechanism that 
defines the 5′ss of exon 7 [43, 44, 83, 84]. These studies culminated in discoveries that led 
to the first therapy for SMA.
3.2. Effect of Terminal Stem Loop 2
In order to demonstrate the role of an RNA structure in pre-mRNA splicing, one must first 
perform structure probing to definitively confirm the existence of a specific RNA structure. 
In addition, using site-specific mutagenesis one must then show a correlation between 
disruption of the structure and altered splicing. Validating experiments must also 
demonstrate that the splicing pattern is restored when the structure is reinstated. Thus far 
only a handful of studies have fulfilled the above-mentioned requirements to conclusively 
establish the role of an RNA structure in pre-mRNA splicing. Inspired by the results of in 
vivo selection, we performed a systematic study uncovering the role of the terminal stem-
loop 2 (TSL2) predicted to partially sequester the 5′ss of exon 7 in splicing regulation of 
this exon (Fig. 2C). Enzymatic structure probing confirmed the existence of both TSL1 and 
TSL2 [82]. Supporting the inhibitory role of TSL2, U40G or A54C substitution that 
disrupted TSL2 was found to promote SMN2 exon 7 inclusion. As expected, when U40G 
and A54C substitutions were combined to reinstate the TSL2 structure, a strong inhibitory 
effect on SMN2 exon 7 splicing was restored [82]. These results unequivocally confirmed 
that TSL2 plays the inhibitory role in the regulation of SMN exon 7 splicing. One of the 
mechanisms by which TSL2 prevents SMN2 exon 7 inclusion is through poor recruitment of 
U1 snRNP at the 5′ss of exon 7. Consistent with this argument, a mutated U1 snRNA with 
extended complementarity to the 5′ss of exon 7 was found to restore SMN2 exon 7 
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inclusion [82]. Independently validating these findings, an ASO-mediated depletion of 
endogenous U1 snRNP was found to promote skipping of exon 7 from both SMN1 and 
SMN2 [49]. However, the effect of U1 snRNP depletion was less pronounced in case of 
SMN1 exon 7 than SMN2 exon 7. This could be due to C6U substitution strengthening 
TSL1 and as a consequence stabilizing TSL2. It is also possible that the stimulatory factor(s) 
interacting with SMN1 exon 7 disrupt TSL2.
3.3. Effect of Intronic Splicing Silencer N1
In an effort to identify additional cis-elements that might suppress the recognition of the 5′ss 
of SMN2 exon 7, we analyzed the intronic sequences immediately downstream of the 5′ss 
of exon 7. Using the SMN2 minigene we generated a set of mutants with overlapping 
deletions and tested their splicing pattern. Our results revealed that the sequence spanning 
from the 10th to 24th positions of intron 7 is highly inhibitory for exon 7 inclusion [85]. We 
termed this sequence as intronic splicing silencer N1 or ISS-N1 (Fig. 3; [85]). ISS-N1 
deletion obviated the requirement for several positive cis -elements responsible for SMN 
exon 7 inclusion. We next employed type 1 SMA patient fibroblasts (GM03813) to validate 
the inhibitory effect of ISS-N1 in the context of the endogenous SMN2. Of note, GM03813 
cells carry only SMN2 and offer an invaluable tool to examine the effect of compounds on 
spicing of SMN2 exon 7. As expected, an ASO that blocked ISS-N1 fully restored SMN2 
exon 7 inclusion in GM03813 cells [85]. Importantly, ISS-N1-targeting ASO had a 
pronounced stimulatory effect on SMN2 exon 7 splicing even at a low concentration of 5 
nM. This could be due to strong inhibitory nature of ISS-N1 combined with its high 
accessibility for an ASO that targets it. Among several hundred targets examined thus far, 
ISS-N1 remains the most effective target for an ASO-mediated stimulation of SMN2 exon 7 
inclusion [89]. Numerous studies employing various mouse models have independently 
validated the in vivo efficacy of ISS-N1-targeting ASOs [23]. The recently approved ISS-
N1-targeting drug for SMA, Nusinersen (synonyms: ISIS-SMNRx, IONIS-SMNRx and 
Spinraza™), is a modified oligonucleotide that carries phosphorothioate backbone and 
encompasses methoxyethyl modification at the 2′-hydroxyl position of the revealed that the 
sequence spanning from the 10th to 24th positions of intron 7 is highly inhibitory for exon 7 
inclusion [85].
Among several hundred targets examined thus far, ISS-N1 remains the most effective target 
for an ASO-mediated stimulation of SMN2 exon 7 inclusion [89]. Numerous studies 
employing various mouse models have independently validated the in vivo efficacy of ISS-
N1-targeting ASOs [23]. The recently approved ISS-N1-targeting drug for SMA, Nusinersen 
(synonyms: ISIS-SMNRx, IONIS-SMNRx and Spinraza™), is a modified oligonucleotide 
that carries phosphorothioate backbone and encompasses methoxyethyl modification at the 
2′-hydroxyl position of the sugar moiety [23]. The above-mentioned modifications are 
known to enhance the in vivo stability of oligonucleotides. Multiple reports published 
recently discuss different aspects of the drug development process that led to the FDA 
approval of Nusinersen [25, 26, 49, 90–93]. More than a dozen independent studies 
employing ASOs with different chemistries have validated the stimulatory effect of ISS-N1 
sequestration on SMN2 exon 7 splicing [89, 94]. An in-depth analysis of these studies for an 
improved future ASO-based therapy is beyond the scope of this review.
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Several studies have been performed to uncover the mechanism of ISS-N1 function. The 
inhibitory effect of ISS-N1 was only partially maintained in a heterologous background, 
suggesting that the context of SMN2 makes ISS-N1 a strong negative regulator of splicing 
[85]. An early report implicated two putative-binding sites of hnRNP A/A2 within ISS-N1 
as the major cause of the inhibitory effect of this cis -element (Fig. 3; [52]). This model has 
been recently revised to suggest that two RNA-recognition motifs (RRMs) of a single 
hnRNP A1 molecule interact with two putative sites within ISS-N1 [95]. Noticeably, the 
cytosine residue at the first position (10C) of ISS-N1 does not fall within the putative 
hnRNP A1/A2-binding site. Yet, sequestration of 10C was found to be absolutely critical for 
an ASO-mediated splicing correction of SMN2 exon 7 (Fig. 3 ; [96]). It has been also 
confirmed that ASO-mediated sequestration of two putative hnRNP A1/A2-binding sites 
within ISS-N1 is not enough to produce a stimulatory effect on SMN2 exon 7 splicing [50, 
96]. Overall, several studies suggest a more complex mode of ISS-N1 action. Furthermore, 
motifs upstream and downstream of ISS-N1 appear to be involved in it as well [49, 50, 96, 
97].
In search for the shortest ASO that effectively restores SMN2 exon 7 inclusion, we 
performed an ultra-refined antisense microwalk within and around ISS-N1 sequence [97]. Of 
note, ASO sizes and their respective targets in our ultra-refined antisense microwalk differed 
by single nucleotides. Such approach unequivocally guarantees success for the identification 
of the shortest therapeutic ASO [98]. Our results showed that sequestration of a GC-rich 
sequence (GCRS) by an 8-mer ASO fully restored SMN2 exon 7 inclusion (Fig. 3; [97]). 
Interestingly, GCRS-targeting ASO was found to be more specific than an ISS-N1-targeting 
ASO, particularly at higher concentrations [97]. This is not entirely surprising, since long 
ASOs can tolerate mismatched base pairs, whereas as shorter ASOs require total 
complementarity. Subsequent studies confirmed the therapeutic efficacy of a GCRS-
targeting ASO in both mild and severe mouse models of SMA [99]. Although GCRS 
partially overlaps with ISS-N1, it may represent a distinct negative element. Future studies 
will determine if a specific factor associates with GCRS.
3.4. Effect of U-Rich Clusters Within Intron 7
SMN intron 7 contains multiple U-rich clusters (URCs). URC1 and URC2 are located next 
to each other immediately downstream of ISS-N1 (Fig. 3). Element 2, the very first intronic 
cis-element shown to promote exon 7 inclusion, is located downstream of URC2 [86]. It 
partially overlaps with the third U-rich cluster, URC3 (Fig. 3). Overlapping deletions in the 
SMN2 minigene confirmed the strong stimulatory nature of the above URCs and Element 2. 
Subsequent experiments linked the stimulatory effect of URC1 and URC2 with TIA1, a 
glutamine-rich RNA-binding protein [75]. TIA1 and its related protein TIAR generally 
interact with URCs immediately downstream of a 5′ss and stimulate exon inclusion by 
promoting recruitment of U1 snRNP to suboptimal 5′ss [100]. However, the context of 
TIA1/TIAR interactions in SMN2 intron 7 is somewhat different due to the presence of ISS-
N1 between the 5′ ss of exon 7 and URC1/URC2 sites to which TIA1 binds. 
Overexpression of TIA1 fully restored SMN2 exon 7 inclusion, suggesting that factors that 
interact with ISS-N1 interfere with recruitment of TIA1 to URC1/URC2 [75]. Supporting 
the role TIA1 in SMN exon 7 splicing in the context of a human disease, Welander distal 
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myopathy (WDM) patients carrying a TIA1 mutation display an elevated level of SMN exon 
7 skipping [101]. Recently, mutations in TIA1 have been also linked to frontotemporal 
dementia (FTD) and ALS [102]. However, it is not known if FTD/ALS patients carrying 
TIA1 mutations display SMN exon 7 skipping in any of their tissues. Notably, nervous tissue 
of Tia1 knockout mouse shows dysregulated expression of lipid storage and membrane 
dynamics factors [103]. However, effect of Tia1 deletion on SMN2 exon 7 splicing cannot 
be evaluated because mice lack SMN2. To obviate this problem, we generated a Tia1 
knockout mouse in the context of a mild SMA model harboring SMN2 alleles [104]. 
Interestingly, loss of Tia1 in this mouse model did not show changes in SMN2 exon 7 
splicing, although the severity of the SMA disease was affected in a gender-specific manner 
[104]. Several reasons may account for the discrepancy between the effects of Tia1 deletion 
(in mouse) and TIA1 mutation (in human). For instance, TIA1 is involved in various types of 
protein-protein and RNA-protein interactions during pre-mRNA splicing, stress granule 
formation, and mRNA trafficking [105, 106]. It is likely that a mutant TIA1 protein perturbs 
protein-protein and RNA-protein interactions in the above-mentioned processes. On the 
other hand, the complete loss of Tia1 in the mouse model is tolerated due to the presence of 
its related protein Tiar and/or other glutamine-rich RNA-binding protein.
3.5. Effect of Long-Distance Interactions Within Intron 7
Splicing of SMN exon 7 is modulated by a unique RNA structure formed by long-distance 
interactions (LDI) within intron 7 [43, 50, 96]. This structure is termed as “Internal-Stem 
formed by LDI 1” or ISTL1 (Fig. 4; [50]). Chemical structure probing confirmed the 
formation of ISTL1 along with several other structures within intron 7 (Fig. 4). Two strands 
of ISTL1 are separated from each other by 279-nts, of which 189 residues are located within 
the independently folded modules. The 5′ strand of ISTL1 overlaps with the 5′ss of exon 7 
as well as 10C, which occupies the first position of ISS-N1. It appears that the formation of 
ISTL1 strengthens TSL2. Consistently, F14, a 14-mer ASO that sequesters the first 14 
residues of ISS-N1, including 10 C, destabilizes both ISTL1 and TSL2 [50, 96]. On the 
contrary, L14, a 14-mer ASO that sequesters the last 14 residues of ISS-N1, but not 10 C, 
strengthens both ISTL1 and TSL2. Consequently, F14 and L14 have opposite effects on 
SMN2 exon 7 splicing: F14 promotes SMN2 exon 7 inclusion, while L14 causes skipping of 
this exon [50, 96]. The opposite effects of F14 or L14 were found to be independent of the 
oligonucleotide chemistry, suggesting that ASO-induced structural rearrangement at the 5′ 
ss of exon 7 was the driving force behind the splicing outcomes [96]. This is a rare example 
in which two ASOs of identical size annealing to sequences differing only by a single 
nucleotide produce opposite effects on pre-mRNA splicing. The 3′ strand of ISTL1 overlaps 
with ISS-N2, a negative element located deep within intron 7 (Fig. 4; [50]). ISS-N2 also 
participates in the formation of ISTL2 and ISTL3, other intra-intronic structures formed by 
LDIs (Fig. 4). Formation of ISTL2 sequesters URC2, one of the binding sites of TIA1. 
Similar to ISS-N1, deletion or an ASO-mediated sequestration of ISS-N2 restores SMN2 
exon 7 inclusion. Interestingly, ASO-mediated sequestration of ISS-N1 and ISS-N2 brings 
the similar structural changes at the 5′ ss of SMN2 exon 7, suggesting a common 
mechanism of action. It appears that both ISS-N1- and ISS-N2-targeting ASOs promote 
inclusion of SMN2 exon 7 through abrogation of ISTL1 and an improved recruitment of 
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TIA1 (Fig. 5). In vivo study with an ISS-N2 targeting ASO was recently shown to confer 
gender-specific therapeutic benefits in a mild mouse model of SMA [107].
3.6 Extension of Exon 7 by the Activation of a Cryptic 5′ss
Various instances of SMA caused by enhanced exon 7 skipping triggered by mutations at the 
3′ or the 5′ss of SMN1 exon 7 have been reported [12, 108, 109]. Such patients cannot 
benefit from Nusinersen or any other therapeutic approach requiring the fully functional 
splice sites of exon 7. However, these patients can take advantage of an engineered U1 
snRNA (eU1)-based approach aimed at the activation of a cryptic 5′ss located downstream 
of the natural 5′ss of exon 7. The proof of principle has recently been established in the 
context of a pathogenic G-to-C mutation at the first position (G1C) of SMN1 intron 7 (Fig. 
6; [49]). As expected, SMN1 exon 7 carrying G1C substitution undergoes complete skipping 
of exon 7 with or without an ISS-N1-targeting ASO. However, eU1s targeting ISS-N1 or 
sequences upstream or downstream of this cis-element activate a cryptic 5′ss (Cr1) leading 
to the inclusion of an “extended” exon 7. Of note, another cryptic 5′ss, Cr2, located within 
URC2 could also be activated by a different set eU1s, albeit with less efficiency [49]. Cr1 
and Cr2 usage increases the length of exon 7 by 23 and 51 nts, respectively (Fig. 6). Since 
the stop codon of SMN is located within exon 7, activation of Cr1 or Cr2 will have no 
consequences for the protein. Indeed, the activation of Cr1 in SMN1 construct carrying 
pathogenic G1C mutation led to the production of SMN, confirming that transcripts 
generated by Cr1 activation are stable and translation competent (Fig. 6; [49]).
The discovery of Cr1 and Cr2 brings new perspective to our understanding of SMN exon 7 
splicing regulation. Cr1 partially overlaps with ISS-N1, suggesting that the factors 
interacting with ISS-N1 are likely to suppress the activation of Cr1 as well. Interestingly, 
Cr1 is efficiently activated even by those eU1s that did not anneal to Cr1 directly [49]. Also, 
activation of Cr1 does not require assistance of the endogenous U1 snRNP, suggesting that 
usage of Cr1 can occur in the absence of the typical RNA:RNA duplex formed between the 
5′ss and the U1 snRNA. This finding has broad implications as it suggests that the U1 
snRNP can affect selection of a 5′ss from distance. It appears that positive cis-elements 
required for inclusion of SMN exon 7 are dispensable for Cr1 activation. For instance, point 
mutations that activated Cr1 in SMN2 tolerated the loss of the enhancer associated with 
Tra2-beta1. Further, eU1s targeting Cr1 prevented skipping of exon 7 associated with the 
pathogenic mutation at the 3′ss of SMN1 exon 7. Overall, these findings suggest that the 
activation of Cr1 might employ an entirely different set of rules.
3.7 Role of cis-Elements Within Intron 6
Various mutations at the 3′ss of SMN1 intron 6 have been found to be associated with SMA 
pathogenesis [12, 110, 111]. However, very limited studies have been done to uncover the 
role of cis-elements within SMN intron 6. Element 1, an extended inhibitory sequence 
situated immediately upstream of the 3′ss of exon 7, was the first cis-element to be reported 
within intron 6 (Fig. 3; [87]). Deletion or an ASO-mediated sequestration of Element 1 
promoted SMN2 exon 7 inclusion [87, 112]. A recent report demonstrated an in vivo 
efficacy of an Element 1-targeting ASO in a severe mouse model of SMA [112]. Another 
negative cis -element at the junction of intron 6 and exon 7 has been suggested to constitute 
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a binding site for hnRNP A1 (Fig. 3; [51]). The location of this site right next to the other 
hnRNP A1-binding site created by the C6U mutation within exon 7 strikingly resembles the 
arrangement of two putative hnRNP A1 sites within ISS-N1. As recently proposed, close 
proximity of the two hnRNP A1 sites is conducive for a tight interaction involving two 
RRMs of a single hnRNP A1 molecule [95]. The polypyrimidine tract (PPT) at the 3′ ss of 
exon 7 has been suggested to harbor a positive element associated with hnRNP C (Fig. 3; 
[68]). However, the role of hnRNP C in SMN exon 7 splicing could not be independently 
validated by depletion experiments [48, 113]. Interestingly, an A-to-G substitution at the 
-44th position (A-44G) of intron 6 has been found to promote SMN2 exon 7 inclusion (Fig. 
3; [40]). The A-44G substitution is naturally present in human population and SMA patients 
carrying A-44G substitution show mild phenotype [40].
4. Exonization of an Intronic Alu-Element
Alu elements are primate-specific transposable elements encompassing ~300 bp bipartite 
motifs derived from the 7SL RNA, an essential component of the protein signal recognition 
complex [114]. Insertion of Alu elements has played a significant role in primate evolution 
due to their drastic effect on chromatin remodeling, transcription and generation of novel 
exons [115, 116]. Multi-exon skipping detection assay (MESDA) is a powerful technique 
that simultaneously detects most SMN splice isoforms in a single reaction [117]. Employing 
MESDA, we have recently reported a novel exon, exon 6B, generated by the exonization of 
an Alu element located within intron 6 [33]. Expression of exon 6B-containing transcripts 
has been confirmed in various tissues of a mouse model of SMA as well as in human tissues 
examined [33]. Both SMN1 and SMN2 produce exon 6B-containing transcripts. Generally, 
the right arm of an antisense sequence of an Alu is used for exonization [118]. However, the 
109-nt long exon 6B originated from the left antisense arm of an Alu element. The low 
expression of exon 6B-containing transcripts is attributed to various factors, including 
suppression by hnRNP C and degradation by Nonsense
Mediated Decay (NMD). An overwhelming 39% of SMN sequence is occupied by >40 Alu 
elements located within introns. Exon 6B is the first and only known example of SMN exon 
derived from the exonization of an intronic Alu element. Due to its location upstream of 
exons 7, it is likely that splicing of exon 6B is influenced by exon 7 and vice versa. 
However, the mechanism of exon 6B splicing regulation remains to be determined. Amino 
acids coded by exon 7 define the critical C-terminus of SMN and confer protein stability. 
The loss of amino acids coded by exon 7 is the primary reasons why SMNΔ7 is less stable 
than SMN (Fig. 7; [16, 119]). Irrespective of exon 7 inclusion or skipping, the exon 6B-
containing transcripts code for SMN6B protein in which the last 16 amino acids are coded 
by exon 6B. The altered C-terminus makes SMN6B less stable than SMN. However, 
SMN6B was found to be more stable than SMNΔ7, suggesting that the altered C-terminus of 
SMN6B is not deleterious as observed in case of SMNΔ7 (Fig. 7; [33]). As expected, 
SMN6B retains the ability to interact with Gemin2, a key protein required for most SMN 
functions. Similar to SMN, SMN6B localizes to both, nuclear and cytosolic compartments. 
Hence, it is likely that SMN6B will be able to ameliorate SMA pathology if expressed at 
sufficient levels.
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5. Alternative Splicing of Other SMN Exons
The diversity of SMN splice isoforms is best demonstrated by MESDA, which captures 
susceptibility of various SMN exons to skipping under normal and stress-associated 
conditions [117]. Low levels of exon 3 and exon 5-skipped transcripts are generated under 
normal conditions in most tissues from both SMN1 and SMN2 [117]. SMN2 exons 5 and 7 
become highly susceptible to skipping under the conditions of oxidative stress, although 
skipping of SMN1 exon 5 is also enhanced by oxidative stress. A recent study examined the 
effect of paraquat, an oxidative-stress-causing agent, on splicing of various SMN2 exons in 
different tissues of a transgenic mouse model harboring SMN2 [120]. Findings of this study 
revealed tissue-specific effect of oxidative stress on splicing of various SMN2 exons. For 
instance, skipping of SMN2 exons 3, 5, and 7 was found to be substantially increased under 
oxidative stress in lung as compared to brain and spinal cord, which instead showed 
significant enhancement of SMN2 exons 5 and 7 skipping. The study also captured 
individual differences of the effect of oxidative stress on splicing of various SMN2 exons. 
For example, one of the four animals examined showed enhanced co-skipping of exons 3, 4, 
5, 6 and 7 in liver at 8 h post paraquat treatment. Another animal showed enhanced co-
skipping of exons 3, 5, 6 and 7 in liver at 12 h post paraquat treatment. While reasons for 
these individual differences remain unknown, findings underscore that the rules of stress-
associated splicing regulation should be interpreted with caution.
Depletion of U1 snRNP creates a stress on the splicing machinery as well as on other co-
transcriptional events dependent upon the availability of U1 snRNP [121]. A diverse set of 
SMN transcripts is generated upon depletion of U1 snRNP by an ASO that sequesters the 5′ 
end of endogenous U1 snRNA [49]. MESDA profile of SMN transcripts generated under U1 
snRNP depletion condition is distinct from those observed under the conditions of oxidative 
stress. For example, splicing of all exons was affected under U1 snRNP depletion, whereas 
splicing of SMN2 exons 5 and 7 was the most affected under oxidative stress condition [49, 
117]. Interestingly, skipping of exon 6 was the least among all other internal exons of SMN 
under both U1 snRNP depletion and oxidative stress conditions [49, 117]. This could be 
attributed to relatively high accessibility of the 5′ ss of exon 6 coupled with a strong duplex 
between U1 snRNP and the 5′ ss of exon 6. It is likely that the energy (ATP) deficit created 
by oxidative stress downregulates the biogenesis of snRNPs, particularly U1 snRNP, which 
is generally maintained at a higher level than other snRNPs. It has been recently shown that 
the depletion of DHX9, an RNA helicase that resolves the double-stranded RNA structures, 
enhances the Alu-induced RNA processing defects, including aberrant pre-mRNA splicing 
and circRNA production from transcripts harboring Alu repeats [122]. Similar to snRNP 
biogenesis, RNA helicases require ATP for their function. Therefore, it is likely that large 
RNA:RNA duplexes formed by Alu elements positioned in opposite orientations in SMN 
pre-mRNA are not appropriately resolved by RNA helicases under the conditions of 
oxidative stress. Preliminary analysis of the publicly available circRNA database suggests 
production of circRNAs by SMN [123]. However, it is not known what fraction of SMN 
transcripts make circRNAs and which of the circRNAs are predominantly expressed in most 
cell types. Future studies will determine how Alu elements might impact generation of SMN 
circRNAs under normal and stress-associated conditions in a cell-specific manner.
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6. Effect of Transcription on Splicing of Various SMN Exons
Transcription requires opening of chromatin structure followed by recruitment of 
transcription initiation factors [9]. Transcription in vivo is coupled to splicing through two 
likely mechanisms: “recruitment coupling” and “kinetic coupling” [124]. These two 
mechanisms are not mutually exclusive and it is often difficult to conclusively distinguish 
one mechanism from the other. In case of recruitment coupling, RNA polymerase II (pol II) 
recruits splicing factors at the promoter site and then transports it to the splice sites. In case 
of kinetic coupling, the rate of transcription elongation influences the outcome of splicing. 
The evidence that transcription affects splicing of SMN exon 7 comes from a promoter-
swapping experiment performed in minigene systems. In particular, the replacement of the 
wild-type SMN promoter with CMV or TK promoter caused enhanced skipping of exon 7 in 
both SMN1 and SMN2 minigenes [117]. These results suggested that wild-type promoter 
harbors sequences that are stimulatory for exon 7 splicing. Additional evidence that 
transcription affects SMN splicing comes from small molecules that affect the activity of 
histone acetylases (HATs) and histone deacetylases (HDACs). The former and the latter 
enzymes activate and suppress transcription, respectively. Various HDAC inhibitors, 
including trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and benzamide 
M344, have been shown to modulate splicing of SMN exon 7 [125]. Another mechanism by 
which transcription could modulate splicing of SMN exons is through the regulation of the 
formation of loops within pre-mRNA. PTB and hnRNP A1/A2 have been implicated in 
deciding splicing outcomes through looping out specific sequences [126, 127]. In particular, 
looping out of an exon promotes its skipping, whereas looping out of an intra-intronic 
sequence promotes exon inclusion. Furthermore, a slow elongating pol II might delay the 
formation of a specific loop. Considering that SMN pre-mRNA contains binding sites for the 
loop-forming hnRNP A1/A2 protein, it is highly likely that splicing of various SMN exons 
is regulated by transcription.
7. Conclusions
SMA is one of the leading genetic diseases associated with infant mortality. As soon as the 
association of SMA with SMN1 deletion/mutations was established in 1995, attempts began 
to find a potential cure/therapy for this disorder. Since SMN2 is almost universally present in 
SMA patients, it offers an obvious therapeutic target for exon 7 splicing correction. The 
major breakthrough came when the critical role of the context-specific cis-elements located 
away from the pathogenic mutations, such as C6U, was beginning to be established. In 
particular, the discovery of the intronic cis-element, ISS-N1, reported in 2006 produced an 
effective target, sequestration of which fully corrected SMN2 exon 7 splicing and restored 
SMN levels in SMA patient cells. General interest in ISS-N1 combined with subsequent 
independent validations of its therapeutic potential paved a way to the first FDA-approved 
drug for SMA. In addition, the detailed characterization of ISS-N1 led to the discovery of a 
unique RNA structure formed by long-distance intra-intronic interactions that contributes to 
exon 7 skipping. Interestingly, abrogation of a similar structure within intron 3 of the 
proteolipid protein 1 (PLP1) gene has been recently suggested to cause X-linked Pelizaeus–
Merzbacher disease or PMD [128]. Growing evidence suggests that splicing of various 
exons is differentially regulated under the normal and stress-associated conditions. It is also 
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becoming obvious that the intronic Alu elements are capable of increasing the diversity of 
SMN splice isoforms and may play an important role in the generation of circRNAs [123]. 
Furthermore, new findings that two antisense transcripts are produced from the SMN locus 
highlight the existence of an addition layer of SMN transcription and potentially splicing 
control. The development of novel tools and reliable assays that accurately capture 
transcription-coupled splicing events would tremendously advance our understanding of how 
expression of the SMN gene is regulated, including the pre-mRNA splicing step. This 
advancement would also uncover the likely mechanisms of the tissue-specific modulation of 
splicing of various SMN exons under the normal and stress-associated conditions. A better 
understanding of SMN splicing has implications for several diseases impacted by the low 
levels of the SMN protein. Lessons learnt from SMN would also provide unique insights 
into our understanding of a growing number of human diseases associated with aberrant 
splicing.
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Fig. 1. 
Organization of SMN gene. (A) A view of human SMN1/SMN2 gene(s) located on 
chromosome 5. Exons and introns are shown as boxes and lines, respectively. Loci of 
antisense RNAs, SMN-AS1 [27], and SMN-AS1* [28] are marked with bars. (B) 
Diagrammatic representation of human SMN promoter region. Multiple transcription start 
sites (TSS) identified so far are indicated using arrows. Numbers in brackets correspond to 
their position relative to TSS1a (+1). TSS1a and TSS2 were identified in [29] as 
transcription start sites preferentially used in adult and fetal tissues, respectively. TSS1b was 
mapped in Echaniz-Laguna et al. [30], and TSS3 was identified in Monani et al., [31]. 
Nucleotide differences between the SMN1 and SMN2 promoters are indicated based on 
Monani et al., [31]; [29, 32]), where nucleotide positions were calculated from TSS1a. 
Translation initiation site is marked as Start. (C) Diagrammatic representation of the SMN1/
SMN2 pre-mRNA. Exons and introns are shown as boxes and lines, respectively. Sizes of 
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exons and introns are indicated in nucleotides (nts). The translation initiation and 
termination sites are marked as Start and Stop, respectively. Exon 8 is mostly used as the 3′ 
untranslated region (UTR). The bottom panel indicates nucleotides differences between 
SMN1 and SMN2 in the region located downstream of exon 6B. The last position of intron 
6B is designated as −1. For exons 7 and 8, as well as intron 7, counting starts with the first 
position of the respective exon or intron. (D). Diagrammatic representation of SMN protein 
isoforms. Protein regions encoded by each exon are shown as colored boxes with the number 
of amino acids given. In the top panel, protein domains are indicted above, while SMN 
interacting partners are shown below the diagrammatic representation of the full-length 
SMN. For further details see Singh et al. [13]. The bottom panel shows the known SMN 
isoforms as compared to the full-length SMN protein. These isoforms are generated either 
due to exon 7 skipping or exonization of a region within intron 6 [33] or intron 3 retention 
[34]. The size of each isoform (in amino acids) is given in brackets. Abbreviations are given 
in Table 2
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Fig. 2. 
Exon 7 splicing regulation. (A) Diagrammatic representation of cis-elements and transacting 
factors that modulate SMN exon 7 splicing. Positive and negative elements are indicated by 
(+) and (−), respectively (For further details see [43]). Numbering of nucleotides starts with 
the first position of exon 7. Exonic and intronic sequences are shown in upper- and lower-
case letters, respectively. The 3′ and 5′ss are indicated by arrows. (B) Terminal stem-loop 
structure, TSL1, formed at the beginning of SMN2 exon 7 as determined by enzymatic 
structure probing [44, 45]. Both TSL1 and TSL2 are marked by (−) because they contribute 
toward exon 7 skipping. Numbering of nucleotides starts with the first position of the exon. 
Exonic and intronic sequences are shown in upper- and lower-case letters, respectively. The 
3′ ss is indicated by an arrow. (C) Terminal stem-loop structure, TSL2, formed at the end of 
SMN2 exon 7 as determined by enzymatic structure probing [44, 45]. (−) indicates that 
TSL1 contributes to exon 7 skipping. Numbering of nucleotides starts with the first position 
of the exon. Exonic and intronic sequences are shown in upper- and lower-case letters, 
respectively. The 5′ss is indicated by an arrow. Abbreviations are given in Table 2
Singh and Singh Page 24
Adv Neurobiol. Author manuscript; available in PMC 2018 June 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
Diagrammatic representation of intronic cis-elements and transacting factors that modulate 
SMN exon 7 splicing. Positive and negative elements are indicated by (+) and (−), 
respectively. Positive and neutral numbers indicate nucleotide positions within intron 7 and 
exon 7, respectively, starting with the first intronic/exonic position. Negative numbers 
indicate nucleotide positions within intron 6, starting with the last intronic position. Exonic 
and intronic sequences are shown in upper- and lower-case letters, respectively. Exons and 
introns are also shown as colored boxes and lines. SMN2-spesific single nucleotide 
substitutions are indicated. Intron 7-located ISS-N1, the overlapping GC-rich sequence 
(GCRS) and 10C contribute to skipping of exon 7 [43]. ISS-N1 harbors two hnRNP A1/
A2B1-binding sites that are highlighted in pink. An SMN2-specific C6U substitution in 
exon 7 and A100G substitution in intron 7 create additional binding sites for hnRNP A1 [37, 
47]. Another hnRNP A1-binding site is located at the junction of intron 6 and exon 7 [51]. 
Element 2 and U-rich clusters (URC1 and URC2) are positive cis-elements [75, 86]. TIA1 
interacts with URC1 and URC2 and promotes exon 7 inclusion [75]. Intron 6-located 
Element 1 is highlighted in red [87]. It serves as a binding site for PTB and FUSE-BP [88]. 
A binding site for the stimulatory hnRNP C1/C2 within intron 6 is highlighted in green [68].
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Fig. 4. 
Secondary structure of SMN2 intron 7 derived from chemical probing. Numbering starts 
from the first position of intron 7. Negative numbers represent upstream sequences within 
exon 7. TSLs, ISTLs and binding sites for TIA1 and hnRNP A1/A2B1 are shown and 
highlighted. ISS-N2 is composed of the 3′ strands of ISTL1, ISTL2 and ISTL3 [43, 50]. 
The 5′ss of exon 7 is indicated by a red arrow. Abbreviations are given in Table 2.
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Fig. 5. 
ASO-based mechanism of SMN2 exon 7 splicing correction. Only the relevant sequences of 
exon 7/intron 7 are given. Nucleotide numbering starts from the first position of intron 7. 
ISS-N1 and the binding sites for TIA1 and hnRNP A1/A2B1 are marked by colored boxes. 
The 5′ ss of exon 7 is indicated by a red arrow. The annealing positions of U1 snRNA to 
this 5′ ss are shown. TSL2 and 3 are local RNA secondary structures, while ISTL1, 2 and 3 
are the structures formed by long-distance interactions. These structures are boxed. 
Nusinersen and ASO 283–297 are shown as yellow bars [25, 107]. Their annealing positions 
within intron 7 are indicated. Targeting of the corresponding intronic sequences by 
Nusinersen and ASO 283–297 causes massive structural rearrangements, including 
disruption of TSL3 and ISTL1. As the results TIA1-binding sites become accessible, the 
recruitment of U1 snRNP to the 5′ ss of exon 7 is increased and, in case of Nusinersen, the 
binding of hnRNP A1/A2 to ISS-N1 is blocked. Abbreviations are given in Table 2.
Singh and Singh Page 27
Adv Neurobiol. Author manuscript; available in PMC 2018 June 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 6. 
Effect of an ASO and eU1 on splicing of exon 7. (A) Diagrammatic representation of exon 
7/intron 7 junction. Exonic and intronic sequences are shown in upper- and lower-case 
letters, respectively. Exon7 is also shown as a blue box. Nucleotide numbering starts from 
the first position of intron 7. ISS-N1 and URC1 and URC2 are marked by colored boxes. 
The wild type and the cryptic 5′ ss of exon 7 (Cr1 and 2) are indicated by arrows. GU 
dinucleotides are highlighted in red. (B) Model of how in the context of the intact 5′ ss of 
exon 7 an ASO and eU1 promote production of the full-length SMN protein (Adapted from 
[49]). The ASO block ISS-N1 and eU1 activates usage of the wild-type 5′ ss of exon 7. 
Exons and introns are indicated by the colored boxes and lines, respectively. The ASO is 
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shown as a red bar, and eU1 as a blue structure. ISS-N1, stop codons in exon 7 and 8 and the 
5′ ss of exon 7, wild type and cryptic, are indicated. (C) Model of how in the context of the 
mutated 5′ ss of exon 7 only eU1 promotes production of the full-length SMN protein 
(Adapted from [49]). The G to C mutation at the first position of intron 7 is shown in red. 
The inactivation of the 5′ ss is signified by a red cross. The ASO blocks ISS-N1 and eU1 
activate usage of the cryptic 5′ ss of exon 7, Cr1. Exons and introns are indicated by the 
colored boxes and lines, respectively. The ASO is shown as a red bar, and eU1 as a blue 
structure. ISS-N1, stop codons in exon 7 and 8 and the 5′ ss of exon 7, wild type and 
cryptic, are indicated. Abbreviations are given in Table 2.
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Fig. 7. 
A model showing skipping and inclusion of SMN exon 6B. Exon 6B is derived from an Alu 
element located within SMN intron 6 [33]. Transcripts that include exon 7 but exclude exon 
6B produce full-length SMN, a highly stable protein. Transcripts that lack both exons 6B 
and exon 7 produce SMNΔ7, an unstable and partially functional protein. Transcripts that 
include exon 6B produce SMN6B protein irrespective of inclusion or exclusion of exon 7. 
SMN6B protein is more stable than SMNΔ7 [33]
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Table 2
Abbreviations and terminology used in this study
Abbreviation Full Name Relevant Figures
3′ss 3′ splice site 2
3′-UTR 3′ untranslated region
5′ss 5′ splice site 2
5′-UTR 5′ untranslated region
ASO Antisense oligonucleotide 5
bp Base pair
C6U A C-to-U substitution at the 6th position of SMN2 exon 7 2
Element 1 Negative cis-element located within SMN intron 6 3
Element 2 Positive cis-element located within SMN intron 7 3
eU1 Engineered U1 snRNA 6
hnRNP Hetero-nuclear ribonucleoprotein 2
ISS-N1 Intronic splicing silencer N1 (located within SMN intron 7) 3,5
ISS-N2 Intronic splicing silencer N2 (located within SMN intron 7) 4,5
ISTL1 Internal stem formed by LDI-1 (located within SMN intron 7) 4,5
ISTL2 Internal stem formed by LDI-2 (located within SMN intron 7) 4
ISTL3 Internal stem formed by LDI-3 (located within SMN intron 7) 4
ISTL4 Internal stem formed by LDI-4 (located within SMN intron 7) 4
nt Nucleotide
LDI Long-distance interaction (located within SMN intron 7) 3,4,5
lncRNA Long non-coding RNA 1
Nusinersen An ASO drug that targets ISS-N1 sequence (synonym of Spinraza™) 5
SMA Spinal Muscular Atrophy
SMN (Italics) Survival motor neuron gene or transcript
SMN-AS1 (Italics) Antisense transcript (lncRNA) generated from SMN locus 1
SMN2m SMN2 minigene
SMN2g Endogenous SMN2 gene
SMN-AS1* (Italics) Antisense transcript (lncRNA) generated from SMN locus 1
SMN Survival motor neuron protein
SMN6B SMN6B protein 7
Spinraza™ An ASO drug that targets ISS-N1 sequence (synonym of Nusinersen) 5
TSL1 Terminal stem-loop 1 located within SMN exon 7 2
TSL2 Terminal stem-loop 2 located within SMN exon 7 2,4,5
TSS Transcription start site 1
U1 or U1 snRNA U1 small nuclear RNA 5,6
U1 snRNP U1 small nuclear ribonucleoprotein 5,6
URC1 U-rich cluster 1 located within intron 7 3,5
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Abbreviation Full Name Relevant Figures
URC2 U-rich cluster 2 located within intron 7 3,5
URC3 U-rich cluster 3 located within intron 7 3,5
UTR Untranslated region
wt Wild-type
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